- Home
- AVTX vs ASMB Comparison
AVTX vs ASMB Comparison
Compare AVTX & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- ASMB
- Stock Information
- Founded
- AVTX 2011
- ASMB 2005
- Country
- AVTX United States
- ASMB United States
- Employees
- AVTX N/A
- ASMB N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- ASMB Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- ASMB Health Care
- Exchange
- AVTX Nasdaq
- ASMB Nasdaq
- Market Cap
- AVTX 57.4M
- ASMB 130.2M
- IPO Year
- AVTX 2015
- ASMB 2010
- Fundamental
- Price
- AVTX $5.09
- ASMB $18.14
- Analyst Decision
- AVTX Strong Buy
- ASMB Strong Buy
- Analyst Count
- AVTX 7
- ASMB 3
- Target Price
- AVTX $31.00
- ASMB $33.00
- AVG Volume (30 Days)
- AVTX 122.3K
- ASMB 41.3K
- Earning Date
- AVTX 08-11-2025
- ASMB 08-07-2025
- Dividend Yield
- AVTX N/A
- ASMB N/A
- EPS Growth
- AVTX N/A
- ASMB N/A
- EPS
- AVTX N/A
- ASMB N/A
- Revenue
- AVTX $441,000.00
- ASMB $32,154,000.00
- Revenue This Year
- AVTX N/A
- ASMB $0.04
- Revenue Next Year
- AVTX N/A
- ASMB N/A
- P/E Ratio
- AVTX $0.74
- ASMB N/A
- Revenue Growth
- AVTX N/A
- ASMB 148.33
- 52 Week Low
- AVTX $3.39
- ASMB $7.75
- 52 Week High
- AVTX $16.00
- ASMB $19.93
- Technical
- Relative Strength Index (RSI)
- AVTX 57.49
- ASMB 68.18
- Support Level
- AVTX $4.76
- ASMB $17.45
- Resistance Level
- AVTX $5.05
- ASMB $18.92
- Average True Range (ATR)
- AVTX 0.30
- ASMB 0.87
- MACD
- AVTX 0.03
- ASMB -0.05
- Stochastic Oscillator
- AVTX 84.75
- ASMB 74.68
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.